This clinical trial is focused on studying the effects of a treatment for Rheumatoid Arthritis, a condition that causes pain and swelling in the joints. The treatment being tested is called FBL-MTX, which involves a special form of the medication Methotrexate delivered through a subcutaneous injection, meaning it is injected under the skin. This study aims to understand how effective and safe this treatment is for patients who have not previously used disease-modifying antirheumatic drugs (DMARDs) or for those who have not responded well to or cannot tolerate oral Methotrexate.
The purpose of the study is to evaluate the effectiveness of FBL-MTX in reducing the symptoms of Rheumatoid Arthritis. Participants in the study will receive the treatment over a period of time, with regular check-ups to monitor their progress. The study will look at changes in the disease activity and overall health of the participants at different points during the trial. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.
Throughout the study, the safety and tolerability of the treatment will be closely monitored. This means that any side effects or changes in health will be recorded and assessed. The study will also gather information on how the body processes the medication, which includes measuring the levels of the drug in the blood and how long it stays in the system. The trial is designed to provide valuable insights into the potential benefits and risks of using FBL-MTX for treating Rheumatoid Arthritis.



Portugal